Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 1
2003 1
2005 1
2007 2
2008 1
2009 1
2014 3
2016 1
2018 2
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean stock s (907 results)?
Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma.
Ilhan-Mutlu A, Osswald M, Liao Y, Gömmel M, Reck M, Miles D, Mariani P, Gianni L, Lutiger B, Nendel V, Srock S, Perez-Moreno P, Thorsen F, von Baumgarten L, Preusser M, Wick W, Winkler F. Ilhan-Mutlu A, et al. Among authors: srock s. Mol Cancer Ther. 2016 Apr;15(4):702-10. doi: 10.1158/1535-7163.MCT-15-0582. Epub 2016 Jan 25. Mol Cancer Ther. 2016. PMID: 26809491
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.
Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B; German Chronic Lymphocytic Leukemia Study Group. Huhn D, et al. Among authors: srock s. Blood. 2001 Sep 1;98(5):1326-31. doi: 10.1182/blood.v98.5.1326. Blood. 2001. PMID: 11520778 Free article. Clinical Trial.
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.
Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, Smith I, Thomssen C, Srock S, Sampayo M, Cortes J. Llombart-Cussac A, et al. Among authors: srock s. Breast. 2014 Oct;23(5):656-62. doi: 10.1016/j.breast.2014.06.017. Epub 2014 Jul 19. Breast. 2014. PMID: 25047747 Free article. Clinical Trial.
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. von Minckwitz G, et al. Among authors: srock s. Lancet Oncol. 2014 Oct;15(11):1269-78. doi: 10.1016/S1470-2045(14)70439-5. Epub 2014 Sep 28. Lancet Oncol. 2014. PMID: 25273342 Clinical Trial.
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, Dölken G, Naumann R, Knauf W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grünhagen U; East German Study Group Hematology and Oncology Study. Herold M, et al. Among authors: srock s. J Clin Oncol. 2007 May 20;25(15):1986-92. doi: 10.1200/JCO.2006.06.4618. Epub 2007 Apr 9. J Clin Oncol. 2007. PMID: 17420513 Clinical Trial.
16 results